JP2020516672A5 - - Google Patents

Download PDF

Info

Publication number
JP2020516672A5
JP2020516672A5 JP2019556274A JP2019556274A JP2020516672A5 JP 2020516672 A5 JP2020516672 A5 JP 2020516672A5 JP 2019556274 A JP2019556274 A JP 2019556274A JP 2019556274 A JP2019556274 A JP 2019556274A JP 2020516672 A5 JP2020516672 A5 JP 2020516672A5
Authority
JP
Japan
Prior art keywords
pyrazole
methyl
oxo
benzonitrile
dihydropyridine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2019556274A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020516672A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2018/028097 external-priority patent/WO2018195155A1/en
Publication of JP2020516672A publication Critical patent/JP2020516672A/ja
Publication of JP2020516672A5 publication Critical patent/JP2020516672A5/ja
Priority to JP2023009579A priority Critical patent/JP2023088901A/ja
Pending legal-status Critical Current

Links

JP2019556274A 2017-04-18 2018-04-18 治療用化合物 Pending JP2020516672A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023009579A JP2023088901A (ja) 2017-04-18 2023-01-25 治療用化合物

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201762486894P 2017-04-18 2017-04-18
US62/486,894 2017-04-18
US201862657456P 2018-04-13 2018-04-13
US62/657,456 2018-04-13
PCT/US2018/028097 WO2018195155A1 (en) 2017-04-18 2018-04-18 Therapeutic compounds

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023009579A Division JP2023088901A (ja) 2017-04-18 2023-01-25 治療用化合物

Publications (2)

Publication Number Publication Date
JP2020516672A JP2020516672A (ja) 2020-06-11
JP2020516672A5 true JP2020516672A5 (enExample) 2021-04-30

Family

ID=63791349

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2019556274A Pending JP2020516672A (ja) 2017-04-18 2018-04-18 治療用化合物
JP2023009579A Pending JP2023088901A (ja) 2017-04-18 2023-01-25 治療用化合物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023009579A Pending JP2023088901A (ja) 2017-04-18 2023-01-25 治療用化合物

Country Status (5)

Country Link
US (4) US10617680B2 (enExample)
EP (1) EP3612522A4 (enExample)
JP (2) JP2020516672A (enExample)
TW (2) TWI788343B (enExample)
WO (1) WO2018195155A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10617680B2 (en) * 2017-04-18 2020-04-14 Celgene Quanticel Research, Inc. Therapeutic compounds
IL279734B2 (en) * 2018-06-29 2024-11-01 Forma Therapeutics Inc Inhibiting creb binding protein (cbp)
GB201905721D0 (en) 2019-04-24 2019-06-05 Univ Dundee Compounds
TW202304303A (zh) 2021-04-13 2023-02-01 美商富曼西公司 殺真菌之吡啶酮
JP2024523491A (ja) 2021-06-29 2024-06-28 タイ セラピューティクス リミテッド がんの治療に有用なピロロピリドン誘導体
WO2025010291A2 (en) * 2023-07-03 2025-01-09 The General Hospital Corporation Targeted epigenetic therapies for disorders of progranulin deficiency

Family Cites Families (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3406329A1 (de) 1984-02-22 1985-08-22 Merck Patent Gmbh, 6100 Darmstadt Pyridone
JPH11509835A (ja) 1995-05-19 1999-08-31 ジー.ディー.サール アンド カンパニー 炎症を治療するための置換オキサゾール
WO1997001551A1 (en) * 1995-06-26 1997-01-16 Fujisawa Pharmaceutical Co., Ltd. Pyrazole compounds and pharmaceutical compositions
JP3760957B2 (ja) * 1996-03-05 2006-03-29 信越化学工業株式会社 新規スルホニウム塩及び化学増幅ポジ型レジスト材料
WO2001002400A1 (en) * 1999-07-02 2001-01-11 Eisai Co., Ltd. Fused imidazole compounds and remedies for diabetes mellitus
WO2002078625A2 (en) 2001-03-28 2002-10-10 Pharmacia Corporation Therapeutic combinations for cardiovascular and inflammatory indications
CA2533626A1 (en) * 2003-07-22 2005-02-03 Janssen Pharmaceutica, N.V. Quinolinone derivatives as inhibitors of c-fms kinase
ATE455546T1 (de) * 2003-08-06 2010-02-15 Vertex Pharma Aminotriazol-verbindungen als proteinkinase- hemmer
EP1737841A1 (en) * 2004-04-01 2007-01-03 Astellas Pharma Inc. Pyrazine derivatives and pharmaceutical use thereof as adenosine antagonists
EP1604988A1 (en) * 2004-05-18 2005-12-14 Sanofi-Aventis Deutschland GmbH Pyridazinone derivatives, methods for producing them and their use as pharmaceuticals
GB0420722D0 (en) * 2004-09-17 2004-10-20 Addex Pharmaceuticals Sa Novel allosteric modulators
US7361654B2 (en) * 2005-01-13 2008-04-22 Bristol-Myers Squibb Co. Substituted heteroaryl amide modulators of glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof
JPWO2006137465A1 (ja) * 2005-06-24 2009-01-22 塩野義製薬株式会社 含窒素複素環誘導体
TW200745034A (en) * 2005-09-01 2007-12-16 Astellas Pharma Inc New compounds
WO2007040208A1 (ja) * 2005-10-03 2007-04-12 Ono Pharmaceutical Co., Ltd. 含窒素複素環化合物およびその医薬用途
KR101352973B1 (ko) 2005-10-26 2014-01-22 삼성에스디아이 주식회사 연료전지용 탈황흡착제 및 이를 이용한 탈황방법
WO2007106349A2 (en) * 2006-03-10 2007-09-20 Neurogen Corporation Piperazinyl oxoalkyl tetrahydroisoquinolines and related analogues
JP5182088B2 (ja) * 2006-04-19 2013-04-10 アステラス製薬株式会社 アゾールカルボキサミド誘導体
WO2007139150A1 (ja) * 2006-05-30 2007-12-06 The University Of Tokushima TNFα阻害物質を含有してなる抗インフルエンザウイルス剤
WO2008039882A1 (en) 2006-09-30 2008-04-03 Sanofi-Aventis U.S. Llc A combination of niacin and a prostaglandin d2 receptor antagonist
TW200906825A (en) 2007-05-30 2009-02-16 Scripps Research Inst Inhibitors of protein kinases
US20090054434A1 (en) * 2007-08-23 2009-02-26 Amgen Inc. Isoquinolone derivatives as phosphodiesterase 10 inhibitors
WO2009028543A1 (ja) * 2007-08-30 2009-03-05 Takeda Pharmaceutical Company Limited 置換ピラゾール誘導体
CN102131801B (zh) * 2008-06-25 2015-04-08 福拉姆医药股份有限公司 1,2-二取代的杂环化合物
EP2389227A4 (en) * 2009-01-26 2012-08-08 Intermune Inc METHOD FOR THE TREATMENT OF ACUTE MYOCARDINE CARDS AND ASSOCIATED ILLNESSES THEREOF
GB0919380D0 (en) * 2009-11-04 2009-12-23 Almac Discovery Ltd Pharmaceutical compouds
CN102812022B (zh) * 2010-01-12 2016-02-03 Ab科学有限公司 噻唑和噁唑激酶抑制剂
WO2012020786A1 (ja) 2010-08-11 2012-02-16 日本新薬株式会社 医薬組成物
US9481670B2 (en) 2011-01-25 2016-11-01 Sphaera Pharma Pte. Ltd. Triazine compounds
JP2014122161A (ja) * 2011-03-31 2014-07-03 Astellas Pharma Inc ピラゾール化合物
JP6130383B2 (ja) * 2011-09-30 2017-05-17 エンドゥ ファーマシューティカルズ,インコーポレイティド ピリジン誘導体
WO2013180183A1 (ja) 2012-05-30 2013-12-05 日本新薬株式会社 芳香族複素環誘導体及び医薬
HK1208681A1 (en) 2012-06-12 2016-03-11 Abbvie Inc. Pyridinone and pyridazinone derivatives
AR092742A1 (es) * 2012-10-02 2015-04-29 Intermune Inc Piridinonas antifibroticas
JP2016507496A (ja) * 2012-12-21 2016-03-10 ゼニス・エピジェネティクス・コーポレイションZenith Epigenetics Corp. ブロモドメイン阻害剤としての新規複素環式化合物
JP2016512543A (ja) 2013-03-12 2016-04-28 アッヴィ・インコーポレイテッド ジヒドロ−ピロロピリジノンブロモドメイン阻害剤
US9670221B2 (en) 2013-03-14 2017-06-06 Glaxosmithkline Intellectual Property (No. 2) Limited Furopyridines as bromodomain inhibitors
ES2661012T3 (es) * 2013-03-28 2018-03-27 Takeda Pharmaceutical Company Limited Compuesto heterocíclico
RU2015147601A (ru) 2013-05-01 2017-06-05 Ф. Хоффманн-Ля Рош Аг С-связанные гетероциклоалкилзамещенные пиримидины и их применения
EP3290407B1 (en) * 2013-10-18 2020-01-01 Celgene Quanticel Research, Inc Bromodomain inhibitors
KR102394518B1 (ko) 2014-01-09 2022-05-06 오리온 코포레이션 브로모도메인 억제제로서의 비사이클릭 헤테로사이클릭 유도체
RU2692485C2 (ru) * 2014-04-02 2019-06-25 Интермьюн, Инк. Противофиброзные пиридиноны
CN106794181A (zh) 2014-06-04 2017-05-31 托马斯·黑勒戴药物研究基金会 用于治疗炎性和自身免疫性病况的mth1抑制剂
JP2017528486A (ja) * 2014-09-17 2017-09-28 ヴァーセオン コーポレイション セリンプロテアーゼ阻害剤としてのピラゾリル置換ピリドン化合物
WO2016047678A1 (ja) * 2014-09-25 2016-03-31 武田薬品工業株式会社 複素環化合物
GB201504689D0 (en) * 2015-03-19 2015-05-06 Glaxosmithkline Ip Dev Ltd Chemical compounds
AR104259A1 (es) * 2015-04-15 2017-07-05 Celgene Quanticel Res Inc Inhibidores de bromodominio
EP3322409A4 (en) * 2015-07-15 2019-07-24 Aurigene Discovery Technologies Limited SUBSTITUTED AZA COMPOUNDS AS IRAQ-4 INHIBITORS
CA2992406A1 (en) * 2015-07-15 2017-01-19 Aurigene Discovery Technologies Limited Indazole and azaindazole compounds as irak-4 inhibitors
WO2017026516A1 (ja) * 2015-08-12 2017-02-16 持田製薬株式会社 イソチアゾール誘導体
HK1255102A1 (zh) * 2015-09-21 2019-08-02 Plexxikon Inc. 杂环化合物及其应用
AU2017252276A1 (en) 2016-04-18 2018-11-15 Celgene Quanticel Research, Inc. Therapeutic compounds
AU2017300336B2 (en) 2016-07-18 2021-03-11 National Institute Of Biological Sciences, Beijing Apoptosis inhibitors
US10617680B2 (en) 2017-04-18 2020-04-14 Celgene Quanticel Research, Inc. Therapeutic compounds
AR111479A1 (es) 2017-04-18 2019-07-17 Celgene Quanticel Res Inc Compuestos derivados de piridina y pirazol

Similar Documents

Publication Publication Date Title
RU2481333C2 (ru) Производные 1,1,1-трифтор-2-гидрокси-3-фенилпропана
JP2019519484A5 (enExample)
JP2016512259A5 (enExample)
JP2022531801A5 (enExample)
JP2018118992A5 (enExample)
RU2012146246A (ru) Антибактериальные производные изохинолин-3-илмочевины
ME02437B (me) Disupstituirani oktahidropirolo[3,4-c]piroli kao modulatori oreksin receptora
JP2014531465A5 (enExample)
JP2024521618A5 (enExample)
JP2021501220A5 (enExample)
RU2008141509A (ru) Mglur5 модуляторы 1
JP2019530667A5 (enExample)
JP2020522490A5 (enExample)
HRP20210431T1 (hr) Pripravci tetrahidrokinolina kao inhibitori bet bromodomene
JP2011503166A5 (enExample)
HRP20201746T1 (hr) Aromatski derivati sulfonamida
HRP20211678T1 (hr) N-supstituirani derivati indola kao modulatori receptora pge2
RU2017134901A (ru) Соединения 1-циано-пирролидинов в качестве ингибиторов USP30
JP2007508346A5 (enExample)
JP2008542279A5 (enExample)
JP2007514690A5 (enExample)
RU2015137615A (ru) Замещенные пиридиновые и пиразиновые соединения в качестве ингибиторов pde4
JP2016519096A5 (enExample)
JP2007510689A5 (enExample)
JP2008521900A5 (enExample)